Contract research
It is a long path from the development of an active pharmaceutical ingredient in the lab to an effective drug – a process that takes several years. Campus companies are often involved in this process on behalf of the pharmaceutical and biotech industry or academic groups.
The company Experimental Pharmacology & Oncology Berlin-Buch (EPO) is a leader in preclinical cancer research in Germany. Worldwide, EPO offers customized and comprehensive service for the preclinical development of novel cancer drugs and is specialized in the development of individualized tumor models.
News innovation
Berlin honors outstanding deep-tech companies—including MyoPax
This year, for the first time, a Deep Tech Award was presented in the Bio & Health Tech category. The winner is MyoPax, a spin-off of the Max Delbrück Center and Charité.
more ...Eckert & Ziegler Receives “Best Managed Companies Award” Once Again
Eckert & Ziegler SE (ISIN DE0005659700) has won the “Best Managed Companies Award” for the third time in a row. With this honor, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung, and the Federati...
more ...Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year.
more ...Events Campus
06.06.2026, 17:00
Lange Nacht der Wissenschaften am 6. Juni 2026
Campus Berlin-Buch ist dabei: Von 17 bis 24 Uhr laden dann wieder rund 50 wissenschaftliche und wissenschaftsnahe Einrichtungen in Berlin zu spektakulären Experimenten, spannenden Vorträgen, Wissensch...
more ...09.06.2026, 09:00
Meet the Biotechpark Berlin-Buch at bio:cap 2026
bio:cap 2026: Premiere of a new Life Science & AI Investival at CityCube Berlin
more ...27.08.2026, 10:00
CRISPR/Cas: Grundlagen und praktische Anwendung (Verschoben vom 4. Juni auf 27. August)
Der Crashkurs für Einsteiger*innen vermittelt die Grundlagen der CRISPR/Cas Technologie. Die Teilnehmer*innen sollen in die Lage versetzt werden, CRISPR/Cas Experimente selbständig zu planen und durch...
more ...
